Advanced search

Vol 52, No 1 (2021)
Review article
Published online: 2021-02-26

open access

View PDF Download PDF file
Page views 1652
Article views/downloads 1223
Get Citation

Connect on Social Media

Connect on Social Media

Current status and achievements of Polish haemato-oncology

Sebastian Giebel1, Grzegorz Basak2, Maria Bieniaszewska3, Tomasz Czerw1, Anna Czyż4, Joanna Drozd-Sokołowska2, Dominik Dytfeld5, Krzysztof Giannopoulos6, Lidia Gil5, Grzegorz Helbig7, Jerzy Hołowiecki1, Iwona Hus8, Krzysztof Jamroziak89, Wiesław W. Jędrzejczak2, Wojciech Jurczak10, Artur Jurczyszyn11, Ewa Lech-Marańda8, Krzysztof Lewandowski5, Krzysztof Mądry2, Monika Prochorec-Sobieszek12, Tadeusz Robak13, Tomasz Sacha11, Małgorzata Sokołowska-Wojdyło14, Michał Szymczyk9, Jan Walewski9, Agnieszka Wierzbowska13, Dariusz Wołowiec4, Tomasz Wróbel4, Jan Maciej Zaucha3, Jan Styczyński15
DOI: 10.5603/AHP.2021.0003
Acta Haematol Pol 2021;52(1):4-17.

Abstract

The number of newly diagnosed haematological malignancies in Polish adults and children is about 9,000 a year, which constitutes about 5.5% of all malignancies in the country. Adult patients with haematological malignancies are diagnosed and treated in 42 institutions in Poland. The scientific and educational support for this activity is provided under the umbrella of the Polish Society of Haematologists and Transfusiologists (PTHiT, Polskie Towarzystwo Hematologów i Transfuzjologów), the Polish Adult Leukemia Group (PALG), the Polish Lymphoma Research Group (PLRG), the Polish Myeloma Study Group (PMSG), the Polish Myeloma Consortium (PMC), and consultants in haematology. The aim of this position paper is to present the current status and progress in therapy of haematological malignancies in Polish haematology adult centres, focusing on the activity of PALG, PLRG, and PMSG. The achievements of Polish haemato-oncology at the beginning of the third decade of the 21st century are set out in this paper. Polish haemato-oncology today has an important international position based on contributions to the development of knowledge, international cooperation, and a high quality of patient care. In many instances, clinical trials run by Polish collaborative groups have influenced international standards. Polish haematologists have been the authors of treatment recommendations, and their research has indicated areas for further research.

Keywords: Polish Society of Haematologists and TransfusiologistsPolish Adult Leukemia GroupPolish Lymphoma Research GroupPolish Myeloma Study Group

Article available in PDF format

View PDF Download PDF file

References

  1. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwew Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy. http://onkologia.org.pl/raporty/ (October 20, 2020).
  2. Budziszewska BK, Więckowska B, Lech-Marańda E, et al. Zachorowalność i chorobowość na nowotwory układu krwiotwórczego w Polsce (2009–2015) określone na podstawie analizy danych Narodowego Funduszu Zdrowia wykorzystanych w projekcie „Mapy potrzeb zdrowotnych — baza analiz systemowych i wdrożeniowych”. Hematologia. 2017; 8(2): 89–104.
    CrossRef
  3. Holowiecki J, Grosicki S, Robak T, et al. Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004; 18(5): 989–997.
    CrossRefPubMed
  4. Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012; 30(20): 2441–2448.
    CrossRefPubMed
  5. Libura M, Giebel S, Piatkowska-Jakubas B, et al. Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. Blood. 2016; 127(3): 360–362.
    CrossRefPubMed
  6. Pluta A, Robak T, Wrzesien-Kus A, et al. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. Am J Hematol. 2017; 92(4): 359–366.
    CrossRefPubMed
  7. Budziszewska BK, Pluta A, Sulek K, et al. Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study. Leuk Lymphoma. 2015; 56(8): 2331–2338.
    CrossRefPubMed
  8. Wrzesień-Kuś A, Robak T, Lech-Marańda E, et al. Polish Adult Leukemia Group. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). Eur J Haematol. 2003; 71(3): 155–162.
    CrossRefPubMed
  9. Wrzesień-Kuś A, Robak T, Wierzbowska A, et al. Polish Adult Leukemia Group. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol. 2005; 84(9): 557–564.
    CrossRefPubMed
  10. Wierzbowska A, Robak T, Pluta A, et al. Polish Adult Leukemia Group. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008; 80(2): 115–126.
    CrossRefPubMed
  11. Pluta A, Robak T, Brzozowski K, et al. Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). Leuk Lymphoma. 2020; 61(3): 588–603.
    CrossRefPubMed
  12. Sobas M, Czyż A, Montesinos P, et al. Outcome of a real-life population of patients with acute promyelocytic leukemia treated according to the PETHEMA guidelines: the Polish Adult Leukemia Group (PALG) Experience. Clin Lymphoma Myeloma Leuk. 2020; 20(2): 105–113.
    CrossRefPubMed
  13. Cross NCP, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015; 29(5): 999–1003.
    CrossRefPubMed
  14. Sacha T, Zawada M, Czekalska S, et al. [Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net]. Przegl Lek. 2010; 67(7): 454–459.
    PubMed
  15. Sacha T, Góra-Tybor J, Szarejko M, et al. A multicenter prospective study on efficacy and safety of imatinib generics: a report from Polish Adult Leukemia Group imatinib generics registry. Am J Hematol. 2017; 92(7): E125–E128.
    CrossRefPubMed
  16. Wojtaszewska M, Iwoła M, Lewandowski K. Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms. Acta Haematol. 2015; 133(2): 193–198.
    CrossRefPubMed
  17. Sobieralski P, Leszczyńska A, Bieniaszewska M. Late polycythemic transformation in JAK2-mutated essential thrombocythemia patients-characteristics along with a validation of 2016 WHO criteria. Eur J Haematol. 2019; 103(6): 558–563.
    CrossRefPubMed
  18. Mital A, Prejzner W, Świątkowska-Stodulska R, et al. Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera — retrospective analysis of 142 consecutive cases. Thromb Res. 2015; 136(4): 754–757.
    CrossRefPubMed
  19. Waszczuk-Gajda A, Mądry K, Machowicz R, et al. Red blood cell transfusion dependency and hyperferritinemia are associated with impaired survival in patients diagnosed with myelodysplasticsyndromes: results from the First Polish MDS-PALG Registry. Adv Clin Exp Med. 2016; 25(4): 633–641.
    CrossRefPubMed
  20. Mądry K, Lis K, Biecek P, et al. Predictive model for infection risk in myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia patients treated with azacitidine; azacitidine infection risk model: the Polish Adult Leukemia Group Study. Clin Lymphoma Myeloma Leuk. 2019; 19(5): 264–274.e4.
    CrossRefPubMed
  21. Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, et al. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica. 2009; 94(9): 1236–1241.
    CrossRefPubMed
  22. Helbig G, Stella-Hołowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol. 2008; 141(2): 200–204.
    CrossRefPubMed
  23. Helbig G, Lewandowski K, Świderska A, et al. Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group. Pol Arch Intern Med. 2020; 130(3): 255–257.
    CrossRefPubMed
  24. Giebel S, Holowiecki J, Krawczyk-Kulis M, et al. Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults with acute lymphoblastic leukemia on survival: long-term follow-up of the Polish adult leukemia group 4-96 study. Leuk Lymphoma. 2009; 50(6): 1050–1053.
    CrossRefPubMed
  25. Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, et al. Polish Adult Leukemia Group. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). Ann Hematol. 2006; 85(10): 717–722.
    CrossRefPubMed
  26. Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol. 2008; 142(2): 227–237.
    CrossRefPubMed
  27. Giebel S, Krawczyk-Kulis M, Kyrcz-Krzemien S, et al. Could cytogenetics and minimal residual disease replace conventional risk criteria in adults with Ph-negative acute lymphoblastic leukaemia? Br J Haematol. 2009; 144(6): 970–972.
    CrossRefPubMed
  28. Piatkowska-Jakubas B, Krawczyk-Kuliś M, Giebel S, et al. Polish Adult Leukemia Group. Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group. Pol Arch Med Wewn. 2008; 118(11): 664–669.
    PubMed
  29. Giebel S, Marks DI, Boissel N, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019; 54(6): 798–809.
    CrossRefPubMed
  30. Giannopoulos K, Mertens D, Bühler A, et al. The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia. 2009; 23(3): 519–527.
    CrossRefPubMed
  31. Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol. 2010; 28(11): 1863–1869.
    CrossRefPubMed
  32. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 2000; 96(8): 2723–2729.
    PubMed
  33. Jamroziak K, Grzybowska-Izydorczyk O, Jesionek-Kupnicka D, et al. Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine. Br J Haematol. 2012; 158(2): 286–288.
    CrossRefPubMed
  34. Kalinka-Warzocha E, Wajs J, Lech-Maranda E, et al. Polish Lymphoma Research Group. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. Cancer. 2008; 113(2): 367–375.
    CrossRefPubMed
  35. Walewski J, Paszkiewicz-Kozik E, Michalski W, et al. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Br J Haematol. 2020; 188(6): 898–906.
    CrossRefPubMed
  36. Walewski J, Kraszewska E, Mioduszewska O, et al. Polish Lymphoma Research Group. Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med Oncol. 2001; 18(2): 141–148.
    CrossRefPubMed
  37. Jurczak W, Hubalewska-Dydejczyk A, Giza A, et al. Radioimmunotherapy in follicular lymphomas, a retrospective analysis of the Polish Lymphoma Research Group's (PLRG) experience. Nucl Med Rev Cent East Eur. 2007; 10(2): 91–97.
    PubMed
  38. Bednaruk-Młyński E, Pieńkowska J, Skórzak A, et al. Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma. Leuk Lymphoma. 2015; 56(2): 377–382.
    CrossRefPubMed
  39. Zaucha JM, Malkowski B, Chauvie S, et al. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study. Ann Oncol. 2017; 28(12): 3051–3057.
    CrossRefPubMed
  40. Knopińska-Posłuszny W, Kulikowski W, Paszkiewicz-Kozik E, et al. The use of bendamustine with gemcitabine and dexamethasone in the treatment of primary resistant and relapsed Hodgkin's lymphoma — a multicentre observational study of the Polish Lymphoma Research Group (PLRG) . Acta Haematol Pol. 2015; 46(Suppl): 58–9.
  41. Jurczak W, Ochrem B, Giza A, et al. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group. Pol Arch Med Wewn. 2015; 125(10): 741–748.
    CrossRefPubMed
  42. Jurczak W, Szmit S, Sobociński M, et al. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study. Int J Cardiol. 2013; 168(6): 5212–5217.
    CrossRefPubMed
  43. Szmit S, Jurczak W, Zaucha JM, et al. Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. J Am Soc Hypertens. 2014; 8(11): 791–799.
    CrossRefPubMed
  44. Długosz-Danecka M, Gruszka AM, Szmit S, et al. Primary cardioprotection reduces mortality in lymphoma patients with increased risk of anthracycline cardiotoxicity, treated by R-CHOP regimen. Chemotherapy. 2018; 63(4): 238–245.
    CrossRefPubMed
  45. Drozd-Sokolowska J, Zaucha JM, Biecek P, et al. Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP - the PLRG report. Sci Rep. 2020; 10(1): 3517.
    CrossRefPubMed
  46. Długosz-Danecka M, Hus I, Puła B, et al. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis. Pharmacol Rep. 2019; 71(3): 473–477.
    CrossRefPubMed
  47. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007; 109(9): 3672–3675.
    CrossRefPubMed
  48. Robak T, Błasińska-Morawiec M, Krykowski E, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma. 1996; 22(1-2): 107–111.
    CrossRefPubMed
  49. Czyz A, Romejko-Jarosinska J, Helbig G, et al. Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis. Ann Hematol. 2013; 92(7): 925–933.
    CrossRefPubMed
  50. Maciejka-Kemblowska L, Chaber R, Wrobel G, et al. Clinical features and treatment outcomes of peripheral T-cell lymphoma in children. A current data report from Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG). Adv Med Sci. 2016; 61(2): 311–316.
    CrossRefPubMed
  51. Hermine O, Hoster E, Walewski J, et al. European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016; 388(10044): 565–575.
    CrossRefPubMed
  52. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012; 367(6): 520–531.
    CrossRefPubMed
  53. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial. J Clin Oncol. 2020; 38(3): 248–256.
    CrossRefPubMed
  54. Mead GM, Sydes MR, Walewski J, et al. UKLG LY06 collaborators. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002; 13(8): 1264–1274.
    CrossRefPubMed
  55. Hoelzer D, Walewski J, Döhner H, et al. German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014; 124(26): 3870–3879.
    CrossRefPubMed
  56. Sokolowska-Wojdylo M, Florek A, Zaucha JM, et al. Polish Lymphoma Research Group experience with bexarotene in the treatment of cutaneous T-cell lymphoma. Am J Ther. 2016; 23(3): e749–e756.
    CrossRefPubMed
  57. Iżykowska K, Rassek K, Żurawek M, et al. Hypomethylation of the promoter region drives ectopic expression of TMEM244 in Sézary cells. J Cell Mol Med. 2020; 24(18): 10970–10977.
    CrossRefPubMed
  58. Olszewska B, Żawrocki A, Lakomy J, et al. Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndrome. Int J Dermatol. 2020; 59(9): 1106–1112.
    CrossRefPubMed
  59. Sokołowska-Wojdyło M, Blażewicz I, Olszewska B, et al. Phase 1b study evaluating the safety and efficacy of topical administration of WP1220, a STAT3 inhibitor, for mycosis fungoides (MF). 4th World Congress of Cutaneous Lymphomas (abstract). Barcelona, 2020.
  60. Dmoszynska A, Walter-Croneck A, Hus I, et al. The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group. Leuk Res. 2010; 34(10): 1330–1335.
    CrossRefPubMed
  61. Usnarska-Zubkiewicz L, Dębski J, Butrym A, et al. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group. Leuk Res. 2016; 40: 90–99.
    CrossRefPubMed
  62. Charlinski G, Grzasko N, Jurczyszyn A, et al. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience. Eur J Haematol. 2018; 101(3): 354–361.
    CrossRefPubMed
  63. Grzasko N, Hajek R, Hus M, et al. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leuk Lymphoma. 2017; 58(9): 1–15.
    CrossRefPubMed
  64. Walter-Croneck A, Grzasko N, Soroka-Wojtaszko M, et al. Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group. Leuk Res. 2014; 38(7): 788–794.
    CrossRefPubMed
  65. Hus I, Mańko J, Jawniak D, et al. High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. Oncol Lett. 2019; 18(6): 5811–5820.
    CrossRefPubMed
  66. Giannopoulos K, Jamroziak K, Usnarska-Zubkiewicz L, et al. Recommendations of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma and other plasmacytic dyscrasias for 2018/2019. Acta Haematol Pol. 2018; 49: 157–206.
    CrossRef
  67. Szpiczak plazmocytowy. Ocena jakości informacyjnej rejestru kontraktowego. https://zdrowedanenfzgovpl/course/viewphp? (October 20, 2020).
  68. Jurczyszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016; 91(6): 575–580.
    CrossRefPubMed
  69. Jurczyszyn A, Radocha J, Davila J, et al. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018; 180(6): 831–839.
    CrossRefPubMed
  70. Jurczyszyn A, Castillo JJ, Avivi I, et al. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019; 60(1): 118–123.
    CrossRefPubMed
  71. Jurczyszyn A, Waszczuk-Gajda A, Castillo JJ, et al. Primary refractory multiple myeloma: a real-world experience with 85 cases. Leuk Lymphoma. 2020; 61(12): 2868–2875.
    CrossRefPubMed
  72. Goldman-Mazur S, Jurczyszyn A, Castillo JJ, et al. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Am J Hematol. 2020; 95(5): 503–509.
    CrossRefPubMed
  73. Jurczyszyn A, Gozzetti A, Gdula-Argasińska J, et al. Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. Ann Hematol. 2017; 96(10): 1693–1698.
    CrossRefPubMed
  74. Jurczyszyn A, Nahi H, Avivi I, et al. Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. Br J Haematol. 2016; 175(5): 884–891.
    CrossRefPubMed
  75. Giebel S, Kruzel T, Czerw T, et al. Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers. Bone Marrow Transplant. 2013; 48(7): 915–921.
    CrossRefPubMed
  76. Giebel S, Sadus-Wojciechowska M, Halaburda K, et al. Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group. Ann Hematol. 2016; 95(2): 263–269.
    CrossRefPubMed
  77. Czerw T, Sadus-Wojciechowska M, Michalak K, et al. Increased efficacy ofstem cell chemomobilization with intermediate-dose cytarabine plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone in patients with multiple myeloma: results of a randomized trial. Biol Blood Marrow Transplant. 2019; 25(2): 248–255.
    CrossRefPubMed
  78. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003; 102(3): 814–819.
    CrossRefPubMed
  79. Karabon L, Wysoczanska B, Bogunia-Kubik K, et al. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Hum Immunol. 2005; 66(6): 700–710.
    CrossRefPubMed
  80. Giebel S, Labopin M, Ibatici A, et al. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. Blood. 2010; 116(1): 122–128.
    CrossRefPubMed
  81. Styczynski J, Gil L, Tridello G, et al. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013; 57(6): 794–802.
    CrossRefPubMed
  82. Styczynski J, Reusser P, Einsele H, et al. Second European Conference on Infections in Leukemia. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009; 43(10): 757–770.
    CrossRefPubMed
  83. Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020; 7(2): e157–e167.
    CrossRefPubMed
  84. Czyżewski K, Styczyński J, Giebel S, et al. for Polish Society of Pediatric Oncology and Hematology and Polish Society of Hematology and Blood Transfusion. Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study. Ann Hematol. 2019; 98(9): 2197–2211.
    CrossRefPubMed
  85. Waszczuk-Gajda A, Drozd-Sokołowska J, Basak GW, et al. Infectious complications in patients with multiple myeloma after high-dose chemotherapy followed by autologous stem cell transplant: Nationwide Study of the Infectious Complications Study Group of the Polish Adult Leukemia Group. Transplant Proc. 2020; 52(7): 2178–2185.
    CrossRefPubMed
  86. Styczyński J, Czyżewski K, Frączkiewicz J, et al. Clinical spectrum and outcome of invasive mucormycosis in children and adults: Polish experience of the decade 2010–2019. Acta Haematol Pol. 2020; 51(3): 157–163.
    CrossRef
  87. Hus I, Piekarska A, Roliński R, et al. Vaccination of adult patients with hematological malignancies and patients with asplenia — guidelines of PTHiT and Infectious Diseases Working Group PALG. Acta Haematol Pol. 2018; 49(3): 93–101.
    CrossRef
  88. Piekarska A, Giebel S, Basak G, et al. Szczepienia ochronne u chorych dorosłych po przeszczepieniu komórek krwiotwórczych – zalecenia sekcji do spraw zakażeń PALG. Acta Haematol Pol. 2017; 48(1): 1–9.
    CrossRef
  89. Kołtan S, Urbańczyk A, Grześk E, et al. Vaccinations in children during and after oncological treatment and in selected hematological diseases: recommendations of the Polish Society of Pediatric Oncology and Hematology. Acta Haematol Pol. 2019; 50(4): 182–91.
    CrossRef
  90. Gil L, Kałwak K, Piekarska A, et al. Antifungal management in adults and children with hematological malignancies or undergoing hematopoietic cell transplantation: recommendations of Polish Society of Hematology and Blood Transfusion, Polish Society of Pediatric Oncology and Hematology, and Polish Adult Leukemia Study Group, 2020. Acta Haematol Pol. 2020; 51(2): 60–72.
    CrossRef
  91. Styczyński J. Prophylaxis vs preemptive therapy in prevention of CMV infection: new insight on prophylactic strategy after allogeneic hematopoietic cell transplantation. Acta Haematol Pol. 2020; 51(1): 17–23.
    CrossRef
  92. Styczyński J. Infections following CAR-T cells therapy: current state-of-the-art review and recommendations. Acta Haematol Pol. 2020; 51(1): 11–16.
    CrossRef
  93. Szumera-Cieckiewicz A, Galazka K, Szpor J, et al. Distribution of lymphomas in Poland according to World Health Organization classification: analysis of 11718 cases from National Histopathological Lymphoma Register project - the Polish Lymphoma Research Group study. Int J Clin Exp Pathol. 2014; 7(6): 3280–3286.
    PubMed
  94. Szumera-Ciećkiewicz A, Wojciechowska U, Didkowska J, et al. Population-based epidemiological data of follicular lymphoma in Poland: 15 years of observation. Sci Rep. 2020; 10(1): 14610.
    CrossRefPubMed
  95. Szumera-Ciećkiewicz A, Rymkiewicz G, Grygalewicz B, et al. Comprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation's 2017 classification. Pol J Pathol. 2018; 69(1): 1–19.
    CrossRefPubMed
  96. Lewandowski K, Warzocha K, Hellmann A, et al. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study. Pol Arch Med Wewn. 2009; 119(12): 789–794.
    PubMed
  97. Kjaer L, Skov V, Andersen MT, et al. Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Eur J Haematol. 2019; 103(1): 26–34.
    CrossRefPubMed
  98. Asp J, Skov V, Bellosillo B, et al. International external quality assurance of JAK2 V617F quantification. Ann Hematol. 2019; 98(5): 1111–1118.
    CrossRefPubMed
  99. Link-Lenczowska D, Pallisgaard N, Cordua S, et al. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs. Ann Hematol. 2018; 97(12): 2299–2308.
    CrossRefPubMed
  100. Luczak M, Kaźmierczak M, Handschuh L, et al. Comparative proteome analysis of acute myeloid leukemia with and without maturation. J Proteomics. 2012; 75(18): 5734–5748.
    CrossRefPubMed
  101. Handschuh L, Kaźmierczak M, Milewski MC, et al. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR. Int J Oncol. 2018; 52(3): 656–678.
    CrossRefPubMed
  102. Nagler A, Baron F, Labopin M, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2021; 56(1): 218–224.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note